EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, ITeos Therapeutics's enterprise value is $-138.75 Mil.
ITeos Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-143.87 Mil. Therefore, ITeos Therapeutics's EV-to-EBITDA for today is 0.96.
The historical rank and industry rank for ITeos Therapeutics's EV-to-EBITDA or its related term are showing as below:
ITOS'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -3.15 Med: 1.32 Max: 32.42
Current: 0.96
During the past 6 years, the highest EV-to-EBITDA of ITeos Therapeutics was 32.42. The lowest was -3.15. And the median was 1.32.
ITOS's EV-to-EBITDA is ranked better than 69.28% of 472
companies
in the Biotechnology industry
Industry Median: 9.095
vs ITOS: 0.96
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
ITeos Therapeutics EV-to-EBITDA Historical Data
The historical data trend for ITeos Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of ITeos Therapeutics's EV-to-EBITDA
For the Biotechnology subindustry, ITeos Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ITeos Therapeutics's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ITeos Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where ITeos Therapeutics's EV-to-EBITDA falls into.
ITeos Therapeutics's current Enterprise Value is $-138.75 Mil.
ITeos Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-143.87 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
ITeos Therapeutics's PE Ratio for today is calculated as:
ITeos Therapeutics's share price for today is $10.78.
ITeos Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.150.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of ITeos Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
ITeos Therapeutics (ITeos Therapeutics) Business Description
ITeos Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of immuno-oncology therapeutics for patients. Its product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ITOS has been successfully added to your 